Histone deacetylase 6 as a novel promising target to treat cardiovascular disease

Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocar...

Full description

Saved in:
Bibliographic Details
Published in:Cancer innovation (Print) 2024-06, Vol.3 (3), p.e114-n/a
Main Authors: Wu, Ya‐Xi, Li, Bing‐Qian, Yu, Xiao‐Qian, Liu, Yu‐Lin, Chui, Rui‐Hao, Sun, Kai, Geng, Dian‐Guang, Ma, Li‐Ying
Format: Article
Language:English
Subjects:
cardiovascular disease
histone deacetylase 6
inhibitor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease. HDAC6 have been found to be a key protein in the tumor–cardiovascular association. HDAC6 inhibitors may have important moderating effects in various types of cardiovascular diseases. HDAC6 inhibitors alone or in combination with other agents have shown promising prospects in the treatment of cardiovascular disease.
ISSN:2770-9191
2770-9183
2770-9183
DOI:10.1002/cai2.114